Expanding Sales of Medical and Dental Testing Equipment and Related Products
First written in FY2016. 6 of 11 entries say "Restated". Latest entry: FY2026.
Ferrotec moved to the "Worse" side of this theme in 2023.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「In the biotechnology and medical fields, we will expand sales of blood analyzers, DNA amplification systems and regenerative medicine equipment that use our thermoelectric-device thermoelectric modules. We will continue to supply ceramic products used in telemedicine equipment.」
The company continues to pursue its strategy of expanding thermoelectric module and ceramic product applications in the medical and biomedical fields. - FY2024WorsenedAnnual report
「Thermoelectric module sales to PCR testing equipment declined sharply, but the decrease was offset by higher sales to the communications sector, particularly high-capacity optical transceivers attracting attention in connection with generative AI, resulting in overall revenue growth.」
Shipments to medical applications and PCR testing equipment declined over the full fiscal year. Meanwhile, the communications sector offset the decline, with trends varying by application. - FY2024-Q3RestatedAnnual report
「Sales declined for thermoelectric modules, mainly because shipments for medical applications, particularly PCR testing systems, decreased.」
Shipments to medical applications, particularly PCR testing equipment, continued to decline, reaffirming the weakening of the company's medical and biomedical business. - FY2024-Q2WorsenedAnnual report
「Sales declined mainly because shipments of our core thermoelectric modules to medical applications, particularly PCR testing equipment, decreased.」
In the medical and biomedical fields, shipments to medical applications, particularly PCR testing equipment, declined, leading to lower thermoelectric module sales. - FY2023Some weakness in medical applications and overall sales growthAnnual report
「Our core thermoelectric modules maintained high sales levels, mainly to mobile communications system equipment for 5G. Although sales to PCR testing equipment in the medical sector stagnated in the second half, overall sales increased substantially.」
Although sales of PCR testing equipment for medical applications stagnated in the second half of the fiscal year, thermoelectric module sales increased substantially overall, with performance in the medical and biotechnology fields varying by application. - FY2023-Q1AdvancedAnnual report
「Sales of our core thermoelectric modules to automotive climate-controlled seats weakened, but sales to mobile communications system equipment for 5G, the semiconductor sector and the medical sector increased.」
The company stated that sales of thermoelectric modules for the medical sector increased, indicating progress in expansion into medical testing equipment and other applications. - FY2022-Q3RestatedAnnual report
「Our core thermoelectric modules have maintained stable sales to mobile communications system equipment for 5G and medical testing equipment, including PCR equipment,」
The company explained that sales to 5G mobile communications system equipment and medical testing equipment, including PCR equipment, have continued steadily. - FY2021-Q2RestatedAnnual report
「Business for equipment for next-generation 5G mobile communications systems and medical testing equipment, including PCR systems, performed as planned.」
The company explained that expansion into 5G communications equipment and medical testing equipment, including PCR equipment, is progressing as planned. - FY2020RestatedAnnual report
「In the biotechnology and medical fields, we will expand sales of DNA amplification systems, including PCR testing equipment, blood analyzers and regenerative medicine equipment that use our thermoelectric-device thermoelectric modules. We will continue to supply ceramic products used in telemedicine equipment.」
The company reaffirmed its strategy of expanding sales to PCR testing equipment, blood analyzers, regenerative medicine equipment and telemedicine equipment. - FY2018RestatedAnnual report
「③ In the biomedical field, we will expand sales into DNA amplification systems and blood analysers using thermoelectric elements, regenerative-medicine equipment and other products.」
In the medical and biomedical fields, the company has defined a strategy to expand sales of DNA amplification systems, blood analyzers and regenerative medicine equipment. - FY2016First statedAnnual report
「② Expansion of sales of medical and dental testing equipment and related equipment」
The company explicitly stated that expanding sales is part of its short-term business strategy.